Guideline Adherence of Monitoring Antipsychotic Use for Nonpsychotic Indications in Children and Adolescents
Authors:
- Mariken Msc DinnissenMDMariken Msc Dinnissen
- Andrea DietrichADAndrea Dietrich
- Judith H. Msc van der MolenJMJudith H. Msc van der Molen
- Anne M. Msc VerhallenAVAnne M. Msc Verhallen
- Ynske Msc BuiteveldYBYnske Msc Buiteveld
- Suzanne Msc JongejanSJSuzanne Msc Jongejan
- Pieter W. TroostPTPieter W. Troost
- Jan K. BuitelaarJBJan K. Buitelaar
- Barbara J. van Den HoofdakkerBHBarbara J. van Den Hoofdakker
- Pieter J. HoekstraPHPieter J. Hoekstra
Open Access
- 29 December 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 41 (1) , 13-18
Abstract
Background: Antipsychotics are frequently prescribed to children and adolescents for nonpsychotic indications. Guidelines recommend regularly assessing treatment response and adverse effects and the ongoing need for their use. We aimed to assess adherence to recommendations of available guidelines regarding monitoring antipsychotic use and to test the influence of children's age, sex, intelligence quotient, and diagnosis on adherence. Methods: We reviewed 426 medical records from 26 centers within 3 large Dutch child and adolescent psychiatry organizations, excluding children with schizophrenia, psychosis, mania, or an intelligence quotient below 70. We investigated whether there was regular assessment of treatment response, adverse events (physical and laboratory), and at least annual discussion of the need of continued use. Results: On average, treatment response was assessed in 69.3% of the recommended treatment periods, height in 25.6%, weight in 30.6%, blood pressure in 20.6%, evaluation of adverse events in 19.4%, and cardiometabolic measures in 13.7%; discontinuation and/or continued need was discussed at least annually in 36.2%. Extrapyramidal and prolactin-related adverse effects, waist circumference, glucose, and lipids were rarely investigated. Higher age was associated with lower rates of assessment of treatment response. Most antipsychotics were prescribed long-term. In those children with sufficient documentation of the course of treatment, 57.7% was still using an antipsychotic 3 years after initiation. Conclusions: Our findings indicate insufficient adherence to guideline recommendations for monitoring antipsychotic use in children and adolescents, as well as long duration of use in the majority of children. Especially, older children are at higher risk of receiving suboptimal care.Keywords
This publication has 39 references indexed in Scilit:
- Atypical Antipsychotics for the Treatment of Disruptive BehaviorPediatric Annals, 2013
- Evaluation of Monitoring for Metabolic Effects in Children Treated With Second Generation Antipsychotics in a Pediatric ClinicThe Journal of Pediatric Pharmacology and Therapeutics, 2013
- Treatment of Maladaptive Aggression in Youth: CERT Guidelines II. Treatments and Ongoing ManagementPediatrics, 2012
- Metabolic Screening in Children Receiving Antipsychotic Drug TreatmentArchives of Pediatrics & Adolescent Medicine, 2010
- Practice Parameter on the Use of Psychotropic Medication in Children and AdolescentsJournal of the American Academy of Child & Adolescent Psychiatry, 2009
- Practice Parameter for the Assessment and Treatment of Children and Adolescents With Oppositional Defiant DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 2007
- Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar DisorderJournal of the American Academy of Child & Adolescent Psychiatry, 2007
- Consensus Development Conference on Antipsychotic Drugs and Obesity and DiabetesDiabetes Care, 2004
- Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). Part IIJournal of the American Academy of Child & Adolescent Psychiatry, 2003
- Effects of Development on Olanzapine-Associated Adverse EventsJournal of the American Academy of Child & Adolescent Psychiatry, 2002